Integrative multiomic and immune profiling of lung adenocarcinoma: molecular landscapes, gene expression, and treatment response insights
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf191 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Honghong Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Air Force Medical Center, Fourth Military Medical University, Beijing 100142, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is a major cause of cancer death. Traditional histopathological classification overlooks molecular heterogeneity, limiting personalized treatment. This study used multiomic data to define LUAD subtypes, assess prognostic significance, and analyze immune features, aiming to improve targeted therapy and clinical outcomes.
Methods
This study used Consensus Clustering and Gap Statistics to analyze LUAD multiomic data, including mRNA, lncRNA, miRNA, DNA methylation, and mutations. Clustering was validated by silhouette plots and heatmaps. Molecular characterization involved regulon activity, immune and metabolic profiling. Functional assays (qPCR, WB, CCK-8, flow cytometry) assessed neuronal differentiation factor (NDNF)’s role in LUAD.
Results
Two molecular LUAD subtypes showed distinct clustering and survival outcomes. One subtype had worse prognosis and unique immune features, including checkpoint expression and microenvironment differences. Gene signatures and metabolism varied by subtype. Neuronal differentiation factor was downregulated in tumors; its overexpression suppressed LUAD cell viability and promoted apoptosis, suggesting tumor-suppressive function.
Conclusions
This study identifies 2 LUAD subtypes with distinct molecular and immune features linked to prognosis and therapy response. Neuronal differentiation factor downregulation and its tumor-suppressive effects highlight its therapeutic potential. These findings support improved LUAD stratification and personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Air Force Medical Center, Fourth Military Medical University, Beijing 100142, China.
- Graduate School of China Medical University, Shenyang 110122, China.
- Department of Thoracic Surgery, 962 Hospital of the joint Logistics Support Force, Harbin 150080, China.
- College of Life Sciences, Northwestern University, Xi'an 710069, China.
ORCID-Profile: Yong Han
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- China Postdoctoral Science Foundation
Zitieren
APA
Dong, H., Tian, Y., Guo, Y., Xin, S., Jiang, S., Wan, Z., Wang, H., & Han, Y. (2025). Integrative multiomic and immune profiling of lung adenocarcinoma: molecular landscapes, gene expression, and treatment response insights. The Oncologist. https://doi.org/10.1093/oncolo/oyaf191
Vancouver
Dong H, Tian Y, Guo Y, Xin S, Jiang S, Wan Z, et al. Integrative multiomic and immune profiling of lung adenocarcinoma: molecular landscapes, gene expression, and treatment response insights. The Oncologist. 2025. doi:10.1093/oncolo/oyaf191
BibTeX
@article{Dong2025,
author = {Dong, Honghong and Tian, Yahui and Guo, Yujie and Xin, Shaowei and Jiang, Suxin and Wan, Zitong and Wang, Huaiyu and Han, Yong},
title = {Integrative multiomic and immune profiling of lung adenocarcinoma: molecular landscapes, gene expression, and treatment response insights},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf191}
}
EUVIMED